Certican tabletten (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
67 | Polycystic kidney disease | 2 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-001485-16-AT (EUCTR) | 15/12/2006 | 16/11/2006 | A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD | A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD | polycystic kidney disease MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease | Product Name: Certican Tabletten Product Code: RAD001 INN or Proposed INN: Everolimus | Novartis Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 300 | France;Austria;Germany | |||
2 | EUCTR2006-001485-16-DE (EUCTR) | 25/10/2006 | 19/01/2007 | A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD | A multicenter, randomized, placebo-controlled, double-blind study on the efficacy, safety and tolerability of Certican® in preventing end-stage renal disease (ESRD) in patients with autosomal dominant polycystic kidney disease (ADPKD) - ADPKD | polycystic kidney disease MedDRA version: 8.1;Level: LLT;Classification code 10011771;Term: Cystic kidney disease | Product Name: Certican Tabletten Product Code: RAD001 INN or Proposed INN: Everolimus | Novartis Pharma GmbH | NULL | Not Recruiting | Female: yes Male: yes | 300 | France;Austria;Germany |